Phillips 66 PSX
Phillips 66 has lost investor trust by taking its eye off refining; adding two refining-experienced directors — and Marathon's 2019 playbook if targets slip — unlocks ~75% upside to $205+.
Thesis
Phillips 66 has underperformed Valero and Marathon meaningfully over the past 1-, 3-, 5- and 10-year windows because CEO Mark Lashier and his team 'took their eye off the ball' in Refining — opex/bbl ballooned to a ~$2.30 gap vs Valero while Marathon closed its gap to ~$0.30. Management's 2022 plan ($14bn mid-cycle EBITDA by 2025, $3bn of asset sales, higher capital returns) implies $205+/share and 74% upside, but investors will not underwrite execution given the failed 2019 AdvantEdge66 cost program. Elliott, holding a $1bn stake, demands two new directors with refining-operating expertise to oversee delivery. If 2025 targets slip, Elliott wants a Marathon-style pivot: management changes, closing the refining EBITDA gap to Valero, and $15-20bn of proceeds from selling CPChem, European convenience stores and non-operated midstream stakes to fund a best-in-class capital-return program.
SCQA
Phillips 66, the 2012 ConocoPhillips spin-out, is a major integrated refiner that plays a critical role across the US energy value chain, with refining, midstream, chemicals (CPChem) and marketing operations.
Management 'took its eye off the ball' in Refining — opex/bbl ballooned to a ~$2.30 gap versus Valero, and the 2019 AdvantEdge66 cost program failed, destroying investor trust in the 2025 targets and driving severe TSR underperformance.
Appoint two directors with refining-operating expertise to oversee execution; if the Company fails to show material progress toward its 2025 targets within a year, pursue a Marathon-style pivot with management changes and major non-core divestitures.
Hitting the $14bn 2025 mid-cycle EBITDA target implies $9bn of FCF, a $205+ share price and ~74% upside; the alternative Marathon playbook would additionally unlock $15-20bn from CPChem, European c-stores and midstream monetizations.
The three reasons
- 1
Phillips 66 opex/bbl gap to Valero grew to ~$2.30 while Marathon closed its gap to ~$0.30
- 2
$14bn 2025 mid-cycle EBITDA target implies $9bn FCF and >$205/share — ~74% upside
- 3
Elliott's 2019 Marathon playbook drove ~200% outperformance — a proven precedent
Primary demands
- Appoint two new directors with refining-operating experience to the Phillips 66 Board
- Execute on management's 2025 mid-cycle targets ($14bn EBITDA, $3bn of non-core asset sales, enhanced capital return)
- If 2025 targets are missed, pursue Marathon-style pivot: management change, close the refining EBITDA gap to Valero, monetize CPChem, European convenience stores and non-operated midstream stakes
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Marathon Petroleum transformation under Elliott's 2019 engagement (Mike Hennigan as CEO, ~200% peer outperformance)
- Marathon's Speedway divestiture ($17bn after-tax proceeds funding capital return)
Notable slides (4)
Notes
Six-page Word-style letter with embedded charts (TSR peer-gap bars, opex/bbl line chart, valuation table, Marathon-since-engagement TSR chart). Signed by John Pike (Partner) and Mike Tomkins (Portfolio Manager). $1bn stake disclosed in dollars but no ownership percentage. Notable rhetorical move: Elliott cites its own prior Marathon 2019 campaign as the template ('follow a path that mirrors Marathon's recent transformation'), making this both a thesis letter and a self-branding piece for Elliott's refining playbook. CEO Lashier is quoted ('taken our eye off the ball') but somewhat defended — framing positions the Board, not Lashier personally, as the primary accountability target. Ask is measured/collaborative in tone while carrying an implicit two-step escalation (directors now, breakup if targets slip in a year).